Osanni Bio Closes $190 Million Series B Financing Led by Patient Square Capital
Osanni Bio LLC (“Osanni” or “the Company”), a development-stage therapeutics platform reinventing discovery and development of new medicines, today announced the close of a $190 million Series B financing. The round was led by Patient Square Capital (“Patient Square”), a leading health care investment firm, with participation by existing investors the Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund.
